Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects

Neuroendocrinology

Volumn 100, Issue 1, 2014, Pages 17-25

  Seibert, Julia ^a   Hysek, Cédric M ^b   Penno, Carlos A ^a   Schmid, Yasmin ^b   Kratschmar, Denise V ^a   Liechti, Matthias E ^b   Odermatt, Alex ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Aldosterone; Cortisol; MDMA; Methylphenidate; Steroid; Testosterone

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALDOSTERONE; ANDROSTENEDIONE; CORTICOSTERONE; CORTISONE; DEHYDROCORTICOSTERONE; DEOXYCORTICOSTERONE; DOPAMINE; HYDROCORTISONE; METHYLPHENIDATE; NORADRENALIN; PRASTERONE; PRASTERONE SULFATE; SEROTONIN; STEROID; TESTOSTERONE; PSYCHOTROPIC AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; CORTICOSTERONE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RADIOIMMUNOASSAY; STEROID BLOOD LEVEL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; LIQUID CHROMATOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TIME; YOUNG ADULT;

CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOTROPIC DRUGS; STEROIDS; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 84912522864     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000364879     Document Type: Article

References (59)

1. Armario A: Activation of the hypothalamicpituitary-adrenal axis by addictive drugs: Different pathways, common outcome. Trends Pharmacol Sci 2010; 31: 318-325.
2. Swerdlow NR, Koob GF, Cador M, Lorang M, Hauger RL: Pituitary-adrenal axis responses to acute amphetamine in the rat. Pharmacol Biochem Behav 1993; 45: 629-637.
3. Rivier C, Lee S: Stimulatory effect of cocaine on ACTH secretion: Role of the hypothalamus. Mol Cell Neurosci 1994; 5: 189-195.
4. Sarnyai Z, Biro E, Telegdy G: Cocaine-induced elevation of plasma corticosterone is mediated by different neurotransmitter systems in rats. Pharmacol Biochem Behav 1993; 45: 209-214.
5. Borowsky B, Kuhn CM: Monoamine mediation of cocaine-induced hypothalamo-pituitary-adrenal activation. J Pharmacol Exp Ther 1991; 256: 204-210.
6. Zhou Y, Spangler R, Yuferov VP, Schlussmann SD, Ho A, Kreek MJ: Effects of selective D1-or D2-like dopamine receptor antagonists with acute 'binge' pattern cocaine on corticotropinreleasing hormone and proopiomelanocortin mRNA levels in the hypothalamus. Brain Res Mol Brain Res 2004; 130: 61-67.
7. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al: Duloxetine inhibits effects of MDMA ('ecstasy') in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One 2012; 7: E36476.
8. Han DD, Gu HH: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6: 6.
9. Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al: Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. Int J Neuropsychopharmacol 2014; 17: 371-381.
10. Dumont GJ, Verkes RJ: A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 2006; 20: 176-187.
11. Parrott AC: Cortisol and 3,4-methylenedioxymethamphetamine: Neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 2009; 60: 148-158.
12. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT: Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002; 162: 396-405.
13. Hysek CM, Domes G, Liechti ME: MDMA enhances 'mind reading' of positive emotions and impairs 'mind reading' of negative emotions. Psychopharmacology (Berl) 2012; 222: 293-302.
14. Tancer M, Johanson CE: Reinforcing, subjective, and physiological effects of MDMA in humans: A comparison with D -amphetamine and mCPP. Drug Alcohol Depend 2003; 72: 33-44.
15. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-145.
16. Parrott AC, Lock J, Conner AC, Kissling C, Thome J: Dance clubbing on MDMA and during abstinence from ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008; 57: 165-180.
17. Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ: Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J Psychopharmacol 2012; 26: 419-428.
18. Grob CS, Poland RE, Chang L, Ernst T: Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behav Brain Res 1996; 73: 103-107.
19. Oddie CJ, Coghlan JP, Scoggins BA: Plasma desoxycorticosterone levels in man with simultaneous measurement of aldosterone, corticosterone, cortisol and 11-deoxycortisol. J Clin Endocrinol Metab 1972; 34: 1039-1054.
20. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Mutschler N, Halpern J: Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 2002; 27: 71-82.
21. Mello NK, Knudson IM, Kelly M, Fivel PA, Mendelson JH: Effects of progesterone and testosterone on cocaine self-administration and cocaine discrimination by female rhesus monkeys. Neuropsychopharmacology 2011; 36: 2187-2199.
22. West CD, Mahajan DK, Chavre VJ, Nabors CJ, Tyler FH: Simultaneous measurement of multiple plasma steroids by radioimmunoassay demonstrating episodic secretion. J Clin Endocrinol Metab 1973; 36: 1230-1236.
23. Karssen AM, Meijer OC, Van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, et al: Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001; 142: 2686-2694.
24. Odermatt A, Kratschmar DV: Tissue-specific modulation of mineralocorticoid receptor function by 11ß-hydroxysteroid dehydrogenases: An overview. Mol Cell Endocrinol 2012; 350: 168-186.
25. Dotsch J, Dorr HG, Stalla GK, Sippell WG: Effect of glucocorticoid excess on the cortisol/ cortisone ratio. Steroids 2001; 66: 817-820.
26. Nomura S, Fujitaka M, Jinno K, Sakura N, Ueda K: Clinical significance of cortisone and cortisone/cortisol ratio in evaluating children with adrenal diseases. Clin Chim Acta 1996; 256: 1-11.
27. Simmler LD, Hysek CM, Liechti ME: Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 2011; 96: 2844-2850.
28. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M: Low-dose MDMA ('ecstasy') induces vasopressin secretion. Lancet 1998; 351: 1784.
29. Parrott A, Lock J, Adnum L, Thome J: MDMA can increase cortisol levels by 800% in dance clubbers. J Psychopharmacol 2013; 27: 113-114.
30. Brown WA, Corriveau DP, Ebert MH: Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology (Berl) 1978; 58: 189-195.
31. Van Kempen GM, Goekoop JG, Jong HB, Edelbroek PM, de Wolff FA: The plasma level of methylphenidate in the single-dose oral methylphenidate test. Biol Psychiatry 1990; 28: 638-640.
32. Joyce PR, Donald RA, Nicholls MG, Livesey JH, Abbott RM: Endocrine and behavioral responses to methylphenidate in normal subjects. Biol Psychiatry 1986; 21: 1015-1023.
33. Harris DS, Reus VI, Wolkowitz OM, Mendelson JE, Jones RT: Altering cortisol level does not change the pleasurable effects of methamphetamine in humans. Neuropsychopharmacology 2003; 28: 1677-1684.
34. Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J: Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008; 33: 1856-1863.
35. Sofuoglu M, Poling J, Hill K, Kosten T: Atomoxetine attenuates dextroamphetamine effects in humans. Am J Drug Alcohol Abuse 2009; 35: 412-416.
36. White TL, Grover VK, de Wit H: Cortisol effects of D -amphetamine relate to traits of fearlessness and aggression but not anxiety in healthy humans. Pharmacol Biochem Behav 2006; 85: 123-131.
37. Hill SA, Taylor MJ, Harmer CJ, Cowen PJ: Acute reboxetine administration increases plasma and salivary cortisol. J Psychopharmacol 2003; 17: 273-275.
38. Hennig J, Lange N, Haag A, Rohrmann S, Netter P: Reboxetine in a neuroendocrine challenge paradigm: Evidence for high cortisol responses in healthy volunteers scoring high on subclinical depression. Int J Neuropsychopharmacol 2000; 3: 193-201.
39. Maayan R, Yoran-Hegesh R, Strous R, Nechmad A, Averbuch E, Weizman A, et al: Threemonth treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention deficit hyperactivity disorder. Neuropsychobiology 2003; 48: 111-115.
40. Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245-258.
41. Rush CR, Essman WD, Simpson CA, Baker RW: Reinforcing and subject-rated effects of methylphenidate and D -amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 2001; 21: 273-286.
42. Sommers DK, Van Wyk M, Snyman JR: Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Eur J Clin Pharmacol 1994; 46: 441-444.
43. Nash JF Jr, Meltzer HY, Gudelsky GA: Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988; 245: 873-879.
44. Zaretsky DV, Zaretskaia MV, Dimicco JA, Durant PJ, Ross CT, Rusyniak DE: Independent of 5-HT1A receptors, neurons in the paraventricular hypothalamus mediate ACTH responses from MDMA. Neurosci Lett 2013; 555: 42-46.
45. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al: The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ('ecstasy') in humans. Clin Pharmacol Ther 2011; 90: 246-255.
46. Bhagwagar Z, Hafizi S, Cowen PJ: Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology (Berl) 2002; 163: 118-120.
47. Harmer CJ, Bhagwagar Z, Shelley N, Cowen PJ: Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology (Berl) 2003; 167: 112-114.
48. Miller R, Wankerl M, Stalder T, Kirschbaum C, Alexander N: The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: A meta-analysis. Mol Psychiatry 2013; 18: 1018-1024.
49. Yubero-Lahoz S, Ayestas MA Jr, Blough BE, Partilla JS, Rothman RB, de la Torre R, et al: Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain. Eur J Pharmacol 2012; 674: 337-344.
50. Shenker Y, Gross MD, Grekin RJ: Central serotonergic stimulation of aldosterone secretion. J Clin Invest 1985; 76: 1485-1490.
51. Hamidovic A, Childs E, Conrad M, King A, de Wit H: Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug Alcohol Depend 2010; 109: 175-180.
52. Hysek CM, Liechti ME: Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl) 2012; 224: 363-376.
53. Wachtel SR, Charnot A, de Wit H: Acute hydrocortisone administration does not affect subjective responses to D -amphetamine in humans. Psychopharmacology (Berl) 2001; 153: 380-388.
54. Henry JA, Jeffreys KJ, Dawling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy') . Lancet 1992; 340: 384-387.
55. Liechti ME, Kunz I, Kupferschmidt H: Acute medical problems due to ecstasy use. Caseseries of emergency department visits. Swiss Med Wkly 2005; 135: 652-657.
56. Herring NR, Gudelsky GA, Vorhees CV, Williams MT: (+) -Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse 2010; 64: 773-785.
57. Makisumi T, Yoshida K, Watanabe T, Tan N, Murakami N, Morimoto A: Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism. Eur J Pharmacol 1998; 363: 107-112.
58. Fernandez F, Aguerre S, Mormede P, Chaouloff F: Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4-methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats. Eur J Neurosci 2002; 16: 607-618.
59. Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, et al: The harmful health effects of recreational ecstasy: A systematic review of observational evidence. Health Technol Assess 2009; 13: Iii-iv, ix-xii, 1-315.